Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 2498-50-2 | MDL No. : | MFCD00013001 |
Formula : | C7H11Cl2N3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | GHEHNICLPWTXJC-UHFFFAOYSA-N |
M.W : | 208.09 g/mol | Pubchem ID : | 75626 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 3.0 |
Molar Refractivity : | 56.04 |
TPSA : | 75.89 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.78 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.11 |
Log Po/w (WLOGP) : | 2.16 |
Log Po/w (MLOGP) : | 1.64 |
Log Po/w (SILICOS-IT) : | 0.39 |
Consensus Log Po/w : | 1.06 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.13 |
Solubility : | 1.53 mg/ml ; 0.00735 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.3 |
Solubility : | 1.05 mg/ml ; 0.00505 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.74 |
Solubility : | 3.79 mg/ml ; 0.0182 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 3.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.0 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
94.7% | Stage #1: With iron; acetic acid In ethanol; water at 60 - 80℃; for 4 h; Stage #2: With hydrogenchloride In ethanol; water |
In a three-necked flask equipped with a reflux condenser and a mechanical stirrer, 15.0 g of p-nitrobenzamidine IV prepared in Example 2,20ml of acetic acid, 45ml of water and 45ml of ethanol (V water: V ethanol = 1: 1), 60 ° C under reflux stirring to dissolve,20.3 g of iron powder (η p-nitrobenzamidine IV: η iron powder = 1: 4) was further added,Heated to 80 ° C under reflux reaction stirring 4h, filtration.Filtrate with 20percent NaOH to adjust the pH value of 11 ~ 12 after a large number of flocculent insoluble,Filtered with concentrated hydrochloric acid to adjust the pH value of 1 ~ 2, after the concentration of crystallization, the tide at 100 C under the drying,To obtain 17.9 g of p-aminobenzamidine hydrochloride I as a white solid in a yield of 94.7percent, HPLC: 99.51percent. |
[ 6326-27-8 ]
4-Methylbenzimidamide hydrochloride
Similarity: 0.86
[ 20680-59-5 ]
3-Methylbenzimidamide hydrochloride
Similarity: 0.86
[ 206752-36-5 ]
Benzenecarboximidamide hydrochloride hydrate
Similarity: 0.84
[ 6326-27-8 ]
4-Methylbenzimidamide hydrochloride
Similarity: 0.86
[ 20680-59-5 ]
3-Methylbenzimidamide hydrochloride
Similarity: 0.86
[ 206752-36-5 ]
Benzenecarboximidamide hydrochloride hydrate
Similarity: 0.84
[ 6326-27-8 ]
4-Methylbenzimidamide hydrochloride
Similarity: 0.86
[ 20680-59-5 ]
3-Methylbenzimidamide hydrochloride
Similarity: 0.86
[ 206752-36-5 ]
Benzenecarboximidamide hydrochloride hydrate
Similarity: 0.84